{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:40:52Z","timestamp":1769503252938,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,30]]},"DOI":"10.7759\/cureus.27483","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T14:41:29Z","timestamp":1659192089000},"source":"Crossref","is-referenced-by-count":4,"title":["Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Dhan B","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravash","family":"Budhathoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yub Raj","family":"Sedhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram Kaji","family":"Baniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pearlbiga","family":"Karki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinky","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurab","family":"Mainali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshan","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amik","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipen","family":"Kadaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01734.x","article-title":"Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study","volume":"28","author":"Appenrodt B","year":"2008","unstructured":"Appenrodt B, Wolf A, Gr\u00fcnhage F, et al.. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008, 28:1019-25. 10.1111\/j.1478-3231.2008.01734.x","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo V","year":"1996","unstructured":"Arroyo V, Gin\u00e8s P, Gerbes AL, et al.. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996, 23:164-76. 10.1002\/hep.510230122","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01787.x","article-title":"Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study","volume":"103","author":"Singh V","year":"2008","unstructured":"Singh V, Dheerendra PC, Singh B, et al.. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008, 103:1399-405. 10.1111\/j.1572-0241.2008.01787.x","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001277","article-title":"Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study","volume":"31","author":"Yosry A","year":"2019","unstructured":"Yosry A, Soliman ZA, Eletreby R, Hamza I, Ismail A, Elkady MA. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. Eur J Gastroenterol Hepatol. 2019, 31:345-51. 10.1097\/MEG.0000000000001277","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli P","year":"1998","unstructured":"Angeli P, Volpin R, Piovan D, et al.. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998, 28:937-43. 10.1002\/hep.510280407","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000743","article-title":"Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival","volume":"28","author":"Hanafy AS","year":"2016","unstructured":"Hanafy AS, Hassaneen AM. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. Eur J Gastroenterol Hepatol. 2016, 28:1455-61. 10.1097\/MEG.0000000000000743","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04426.x","article-title":"The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites","volume":"32","author":"Misra VL","year":"2010","unstructured":"Misra VL, Vuppalanchi R, Jones D, Hamman M, Kwo PY, Kahi C, Chalasani N. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment Pharmacol Ther. 2010, 32:1044-50. 10.1111\/j.1365-2036.2010.04426.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40899.x","article-title":"The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites","volume":"100","author":"Kalambokis G","year":"2005","unstructured":"Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005, 100:879-85. 10.1111\/j.1572-0241.2005.40899.x","journal-title":"Am J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12304","article-title":"Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis","volume":"17","author":"Guo TT","year":"2016","unstructured":"Guo TT, Yang Y, Song Y, Ren Y, Liu ZX, Cheng G. Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis. J Dig Dis. 2016, 17:11-9. 10.1111\/1751-2980.12304","journal-title":"J Dig Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:b2700. 10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"ref11","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. (2021). Accessed. May 13, 2021: http:\/\/www.covidence.org."},{"key":"ref12","unstructured":"Mean Variance Estimation. (2021). Accessed. April 24, 2021: https:\/\/web.archive.org\/web\/20181224162602\/http:\/www.comp.hkbu.edu.hk\/~xwan\/median2mean.html.."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.ELX.0000433597.15423.45","article-title":"Prevention of paracentesis-induced circulatory dysfunction: Could we use other albumin alternatives?","volume":"3","author":"Alsebaey A","year":"2013","unstructured":"Alsebaey A, Abdel-Razek W, Bassuni A, Rewisha E, Khalil M, Waked I. Prevention of paracentesis-induced circulatory dysfunction: Could we use other albumin alternatives?. Egypt Liver J. 2013, 3:118-25. 10.1097\/01.ELX.0000433597.15423.45","journal-title":"Egypt Liver J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.06.027","article-title":"The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis","volume":"10","author":"Bari K","year":"2012","unstructured":"Bari K, Mi\u00f1ano C, Shea M, et al.. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol. 2012, 10:1169-75. 10.1016\/j.cgh.2012.06.027","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31829ae376","article-title":"Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study","volume":"48","author":"Hamdy H","year":"2014","unstructured":"Hamdy H, ElBaz AA, Hassan A, Hassanin O. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. J Clin Gastroenterol. 2014, 48:184-8. 10.1097\/MCG.0b013e31829ae376","journal-title":"J Clin Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.09.012","article-title":"Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites","volume":"46","author":"Kalambokis G","year":"2007","unstructured":"Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol. 2007, 46:213-21. 10.1016\/j.jhep.2006.09.012","journal-title":"J Hepatol"},{"key":"ref18","article-title":"Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites","volume":"16","author":"Minakari M","year":"2011","unstructured":"Minakari M, Faiiaz L, Rowshandel M, Shavakhi A. Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites. J Res Med Sci. 2011, 16:87-93.","journal-title":"J Res Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13250","article-title":"Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study","volume":"37","author":"Rai N","year":"2017","unstructured":"Rai N, Singh B, Singh A, Vijayvergiya R, Sharma N, Bhalla A, Singh V. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver Int. 2017, 37:406-14. 10.1111\/liv.13250","journal-title":"Liver Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.04.027","article-title":"Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study","volume":"56","author":"Singh V","year":"2012","unstructured":"Singh V, Dhungana SP, Singh B, et al.. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol. 2012, 56:348-54. 10.1016\/j.jhep.2011.04.027","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.9","article-title":"Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study","volume":"108","author":"Singh V","year":"2013","unstructured":"Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Am J Gastroenterol. 2013, 108:560-7. 10.1038\/ajg.2013.9","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0 E","year":"2018","unstructured":"Sol\u00e0 E, Sol\u00e9 C, Sim\u00f3n-Talero M, et al.. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018, 69:1250-9. 10.1016\/j.jhep.2018.08.006","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22247","article-title":"Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome","volume":"48","author":"Kalambokis GN","year":"2008","unstructured":"Kalambokis GN, Tsianos EV. Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome. Hepatology. 2008, 48:686. 10.1002\/hep.22247","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01778.x","article-title":"The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study","volume":"29","author":"Tandon P","year":"2009","unstructured":"Tandon P, Tsuyuki RT, Mitchell L, et al.. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009, 29:169-74. 10.1111\/j.1478-3231.2008.01778.x","journal-title":"Liver Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/82266-midodrine-in-liver-cirrhosis-with-ascites-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:03Z","timestamp":1707507963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/82266-midodrine-in-liver-cirrhosis-with-ascites-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.27483","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}